Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Gavin S. Bennett
Observed names:
Bennett, Gavin,
G Bennett,
G S. Bennett,
G. Bennett,
Gavin Bennet,
Gavin Bennett
show all 6
Institution:
Cambridge Science Centre
Observed institutions:
King's College London,
University of Cambridge,
Cambridge Science Centre,
Bicycle Therapeutics (United Kingdom)
ORCID:
0000-0003-4425-6852
Observed ORCID:
0000-0003-4425-6852
OpenAlex ID:
A5008228016
Chondroitinase ABC promotes functional recovery after spinal cord injury
2002
·
Elizabeth J. Bradbury
, Lawrence D. F. Moon
, et al.
·
Nature
·
2,378
A Rapid and Transient Peripheral Inflammatory Response Precedes Brain Inflammation after Experimental Stroke
2009
·
Katie Z Chapman
, Verity Q Dale
, et al.
·
Journal of Cerebral Blood Flow & Metabolism
·
135
Nerve growth factor induced hyperalgesia in the rat hind paw is dependent on circulating neutrophils
1998
·
G. Bennett
, S. al-Rashed
, et al.
·
Pain
·
125
MMAE Delivery Using the Bicycle Toxin Conjugate BT5528
2020
·
Gavin Bennett
, Amy Brown
, et al.
·
Molecular Cancer Therapeutics
·
106
BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors
2022
·
Michael Rigby
, Gavin Bennett
, et al.
·
Molecular Cancer Therapeutics
·
85
Identification and Optimization of EphA2-Selective Bicycles for the Delivery of Cytotoxic Payloads
2020
·
Gemma E. Mudd
, Amy Brown
, et al.
·
Journal of Medicinal Chemistry
·
80
Bicyclic Peptides as a New Modality for Imaging and Targeting of Proteins Overexpressed by Tumors
2019
·
Matthias Eder
, Silvia Pavan
, et al.
·
Cancer Research
·
70
Immunoglobulin-like domains define the nerve growth factor binding site of the TrkA receptor
1997
·
Paul H. Holden
, Vipin Asopa
, et al.
·
Nature Biotechnology
·
61
Stable and Long-Lasting, Novel Bicyclic Peptide Plasma Kallikrein Inhibitors for the Treatment of Diabetic Macular Edema
2018
·
Daniel P. Teufel
, Gavin Bennett
, et al.
·
Journal of Medicinal Chemistry
·
46
Identification and Structure of the Nerve Growth Factor Binding Site on TrkA
2001
·
Alan G.S. Robertson
, Mark J. Banfield
, et al.
·
Biochemical and Biophysical Research Communications
·
39
Development of a Lc–Ms/Ms Method for the Quantification of Toxic Payload Dm1 Cleaved from Bt1718 in a Phase I Study
2021
·
Catherine Gowland
, Philip Berry
, et al.
·
Bioanalysis
·
37
Neurogenic cutaneous vasodilatation and plasma extravasation in diabetic rats: effect of insulin and nerve growth factor
1998
·
Gavin S. Bennett
, Neil E. Garrett
, et al.
·
British Journal of Pharmacology
·
35
PDF
Pharmacokinetic (PK) assessment of BT1718: A phase I/II a study of BT1718, a first in class bicycle toxin conjugate (BTC), in patients (pts) with advanced solid tumours
2019
·
N. Cook
, U. Banerji
, et al.
·
Annals of Oncology
·
28
Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors
2024
·
Babar Bashir
, Judy S. Wang
, et al.
·
Journal of Clinical Oncology
·
27
PDF
Abstract 1167: Development of BT1718, a novel Bicycle Drug Conjugate for the treatment of lung cancer
2017
·
Gavin Bennett
, Robert Lutz
, et al.
·
Cancer Research
·
22
Development of BT1718, a Bicycle Drug Conjugate® (BDC) targeting MT1-MMP for treatment of solid tumours
2016
·
G. Bennett
, H. Harrison
, et al.
·
European Journal of Cancer
·
20
Achieving multi-isoform PI3K inhibition in a series of substituted 3,4-dihydro-2H-benzo[1,4]oxazines
2008
·
Benjamin Perry
, Rikki Alexander
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
20
Neurogenic oedema and vasodilatation
1998
·
P K. Towler
, G S. Bennett
, et al.
·
Neuroreport
·
18
BT5528-100 phase I/II study of the safety, pharmacokinetics, and preliminary clinical activity of BT5528 in patients with advanced malignancies associated with EphA2 expression.
2020
·
Johanna C. Bendell
, Judy Sing-Zan Wang
, et al.
·
Journal of Clinical Oncology
·
16
CZ415, a Highly Selective mTOR Inhibitor Showing in Vivo Efficacy in a Collagen Induced Arthritis Model
2016
·
Andrew D. Cansfield
, Tammy Ladduwahetty
, et al.
·
ACS Medicinal Chemistry Letters
·
16
A Cancer Research UK phase I/IIa trial of BT1718 (a first in class Bicycle Drug Conjugate) given intravenously in patients with advanced solid tumours.
2018
·
Udai Banerji
, Natalie Cook
, et al.
·
Journal of Clinical Oncology
·
14
Optimization of a series of multi-isoform PI3 kinase inhibitors
2008
·
Benjamin Perry
, Rebekah Beevers
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
10
Abstract C061: BT8009, a Bicycle Toxin Conjugate targeting Nectin-4, shows target selectivity, and efficacy in preclinical large and small tumor models
2019
·
Michael Rigby
, Gavin Bennett
, et al.
·
Molecular Cancer Therapeutics
·
9
Abstract 5144: BT1718, a novel bicyclic peptide-maytansinoid conjugate targeting MT1-MMP for the treatment of solid tumors: Design of bicyclic peptide and linker selection
2017
·
Helen Harrison
, Gavin Bennett
, et al.
·
Cancer Research
·
8
Bioanalysis of the Bicycle®Toxin Conjugate BT5528 and Released Monomethyl Auristatin E via Liquid Chromatography–Tandem Mass Spectrometry
2023
·
Joseph A Tweed
, Fern Adams-Dam
, et al.
·
Bioanalysis
·
7
Show more works
View as search
Works count:
66
Citation count:
3,451
H-index:
18
I10-index:
22
Year
Topic
Type
